Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?

dc.creatorCunha Júnior, Ademar Dantas da
dc.creatorZanette, Dalila Lucíola
dc.creatorPericole, Fernando Vieira
dc.creatorSaad, Sara Teresinha Olalla
dc.creatorCarvalheira, José Barreto Campello
dc.date2021-02-18T23:21:02Z
dc.date2021-02-18T23:21:02Z
dc.date2021
dc.date.accessioned2023-09-26T23:33:24Z
dc.date.available2023-09-26T23:33:24Z
dc.identifierCUNHA JÚNIOR, Ademar Dantas da et al. Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment? Advances in Hematology, p. 1-7, 2021.
dc.identifier1687-9112
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/46103
dc.identifier10.1155/2021/6615684
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8891843
dc.descriptionObesity is increasingly associated with the transformation of monoclonal gammopathy of undetermined significance (MGUS) into multiple myeloma (MM). Obesity, MGUS, and MM share common etiopathogenesis mechanisms including altered insulin axis and the action of inflammatory cytokines. Consistent with this interconnection, metformin could predominantly exert inhibition of these pathophysiological factors and thus be an attractive therapeutic option for MGUS. Despite the possible clinical significance, only a limited number of epidemiological studies have focused on obesity as a risk factor for MGUS and MM. (is review describes multiple biological pathways modulated by metformin at the cellular level and their possible impacts on the biology of MGUS and its progression into MM.
dc.formatapplication/pdf
dc.languagepor
dc.publisherHindawi
dc.rightsopen access
dc.subjectMultiple Myeloma
dc.subjectMonoclonal Gammopathy of Undetermined Significance
dc.subjectObesity
dc.subjectMetformin
dc.subjectPharmaceutical Preparations
dc.subjectMieloma Múltiple
dc.subjectGammopatía Monoclonal de Relevancia Indeterminada
dc.subjectObesidad
dc.subjectMetformina
dc.subjectPreparaciones Farmacéuticas
dc.subjectMyélome multiple
dc.subjectGammapathie monoclonale de signification indéterminée
dc.subjectObésité
dc.subjectMetformine
dc.subjectPréparations pharmaceutiques
dc.subjectMieloma Múltiplo
dc.subjectGamopatia Monoclonal de Significância Indeterminada
dc.subjectObesidade
dc.subjectMetformina
dc.subjectPreparações Farmacêuticas
dc.titleObesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?
dc.typeArticle


Este ítem pertenece a la siguiente institución